Dolphin Medical

Is Dolphin Medical overvalued or undervalued?

As of November 12, 2024, Dolphin Medical's valuation has deteriorated to "risky," with negative financial ratios indicating overvaluation and poor performance compared to peers like Max Healthcare and Apollo Hospitals, alongside a recent stock decline of 3.36%.

As of 12 November 2024, Dolphin Medical's valuation grade has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued based on its current financial ratios, which include a PE ratio of -3.58, an EV to EBITDA of -4.38, and a Price to Book Value of 0.35. These figures suggest that the company is struggling to generate positive earnings and is not effectively utilizing its assets.<BR><BR>When compared to its peers, Dolphin Medical's financial metrics starkly contrast with those of Max Healthcare, which has a PE ratio of 100.29, and Apollo Hospitals, with a PE ratio of 69.03. This highlights the significant gap in valuation and operational performance within the healthcare services sector. Additionally, Dolphin Medical's recent stock performance has lagged behind the Sensex, with a 1-week return of -3.36%, further reinforcing the notion that the company is currently overvalued in the market.

What is the technical trend for Dolphin Medical?

As of January 21, 2025, Dolphin Medical's technical trend is mildly bullish, supported by daily moving averages and monthly indicators, despite some bearish signals from the weekly MACD and Bollinger Bands.

As of 21 January 2025, the technical trend for Dolphin Medical has changed from bullish to mildly bullish. The weekly MACD indicates a mildly bearish stance, while the monthly MACD remains bullish. The daily moving averages show a mildly bullish trend, suggesting some short-term strength. However, the weekly Bollinger Bands are bearish, which adds caution. The KST and OBV on a monthly basis are both bullish, supporting the mildly bullish outlook. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and monthly indicators.

Who are in the management team of Dolphin Medical?

As of March 2020, the management team of Dolphin Medical includes G V Mohan Prasad (Managing Director & CEO), M Lakshmi Sudha (Whole Time Director & CFO), and five non-executive directors: Vinay Vishnuraj Nayak, Narendra Seena Karkera, K Ramana Kumar, along with executive directors Nanapaneni Buddha Sagar and Madala Sesha Ratnam.

As of March 2020, the management team of Dolphin Medical includes the following members:<BR><BR>1. G V Mohan Prasad - Managing Director & CEO<BR>2. M Lakshmi Sudha - Whole Time Director & CFO<BR>3. Vinay Vishnuraj Nayak - Non-Executive & Independent Director<BR>4. Narendra Seena Karkera - Non-Executive & Independent Director<BR>5. K Ramana Kumar - Non-Executive & Independent Director<BR>6. Nanapaneni Buddha Sagar - Executive Director<BR>7. Madala Sesha Ratnam - Executive Director<BR><BR>These individuals play key roles in the governance and operational leadership of the company.

What does Dolphin Medical do?

Dolphin Medical Services Ltd is a micro-cap healthcare company established in 1992, primarily operated by doctors from Andhra Pradesh. As of March 2025, it reported net sales of 1 Cr and a net loss of 1 Cr, with a market cap of INR 3 Cr.

Overview: <BR>Dolphin Medical Services Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Dolphin Medical Services Limited was established in September 1992 and is promoted by doctors from the coastal region of Andhra Pradesh. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 3 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 81 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.08 <BR>Return on Equity: -1.67% <BR>Price to Book: 0.32<BR><BR>Contact Details: <BR>Address: # No 417 Sanali Heavens, Ameerpet Hyderabad Telangana : 500073 <BR>Tel: 91-040-23738877 <BR>Email: dolphinmedicalindia@gmail.com <BR>Website: http://www.dolphinmedicalservices.com

Who are the top shareholders of the Dolphin Medical?

The top shareholder of Dolphin Medical is G V Mohan Prasad, with a 12.71% stake, followed by public shareholder Manish Ramanlal Shah at 1.68%. Individual investors hold a combined 69.81% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Dolphin Medical include G V Mohan Prasad, who holds the highest stake at 12.71%. The highest public shareholder is Manish Ramanlal Shah, with a holding of 1.68%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 69.81% of the shares. There are no institutional holdings or pledged promoter holdings reported.

When is the next results date for Dolphin Medical?

The next results date for Dolphin Medical is January 30, 2026.

The next results date for Dolphin Medical is scheduled for January 30, 2026.

Why is Dolphin Medical Services Ltd falling/rising?

As of 14-Feb, Dolphin Medical Services Ltd's stock price is stable at Rs. 3.48, with a positive performance trend, increasing by 4.82% over the past week and 21.25% year-to-date. Despite a significant drop in delivery volume, the stock remains liquid and has recently reached a new 52-week high.

As of 14-Feb, Dolphin Medical Services Ltd's stock price is currently stable at Rs. 3.48, showing no change (0.00%). However, the stock has demonstrated a positive performance over various periods, which indicates a rising trend in its value. Over the past week, the stock has increased by 4.82%, and over the last month, it has risen by 11.18%. Year-to-date, the stock has appreciated by 21.25%, significantly outperforming the Sensex, which has declined by 3.04% during the same period.<BR><BR>Today, the stock reached a new 52-week high of Rs. 3.48 and has outperformed its sector by 3.11%. Additionally, it is trading above its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which is generally a positive indicator of momentum. <BR><BR>However, there are some concerns regarding investor participation, as the delivery volume has decreased significantly by 78.78% compared to the 5-day average, suggesting a decline in trading activity. Despite this, the stock remains liquid enough for trading, indicating that it can still attract buyers.<BR><BR>In summary, while the stock price is currently stable, the overall upward trend in performance metrics and recent achievements, such as hitting a new 52-week high, contribute to a perception of rising value for Dolphin Medical Services Ltd.

Which are the latest news on Dolphin Medical?